Enfortumab vedotin in combination with pembrolizumab offers an alternative to platinum-containing chemotherapy for unresectable or metastatic urothelial cancer patients. The positive CHMP opinion is based on a Phase 3 clinical trial showing significant improvements in overall survival and progression-free survival compared to chemotherapy. This combination could change the standard of care for this disease, as current treatment options are limited. If approved by the European Commission, it will be the first-line treatment in EU member states. The impact of this result has already been reflected in Astellas Pharma’s financial forecast, and more information is available in the press release issued on January 29, 2024.
Source link
Astellas receives positive CHMP Opinion for PADCEV™▼ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for first-line treatment of advanced bladder cancer
